--- title: "OmniAb | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 14.43 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285618000.md" datetime: "2026-05-07T20:55:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285618000.md) - [en](https://longbridge.com/en/news/285618000.md) - [zh-HK](https://longbridge.com/zh-HK/news/285618000.md) generator: "portal-rs" --- # OmniAb | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 14.43 M Revenue: As of FY2026 Q1, the actual value is USD 14.43 M, beating the estimate of USD 5.6 M. EPS: As of FY2026 Q1, the actual value is USD -0.06, beating the estimate of USD -0.1. EBIT: As of FY2026 Q1, the actual value is USD -8.316 M. OmniAb, Inc. operates as a single reportable business segment, providing discovery research technology for next-generation therapeutics. The company’s financial performance for the three months ended March 31, 2026, shows significant year-over-year changes in revenue and operational costs, leading to a reduced net loss. #### Segment Revenue - **Total Revenue**: Increased by $10,273 thousand (247%) to $14,427 thousand for the three months ended March 31, 2026, compared to $4,154 thousand in the prior-year period. - **License and Milestone Revenue**: Grew by $10,004 thousand (495%) to $12,025 thousand, up from $2,021 thousand, primarily due to an increase in milestone revenue. - **Service Revenue**: Increased by $204 thousand (11%) to $2,107 thousand from $1,903 thousand, mainly due to an increase in ion channel programs. - **xPloration Revenue**: Increased by $12 thousand (29%) to $54 thousand from $42 thousand. - **Royalty Revenue**: Increased by $53 thousand (28%) to $241 thousand from $188 thousand. #### Operational Metrics - **Net Loss**: Decreased to - $7,707 thousand for the three months ended March 31, 2026, from - $18,200 thousand in the same period last year. - **Loss from Operations**: Reduced to - $7,829 thousand from - $18,844 thousand year-over-year. - **Total Costs and Operating Expenses**: Decreased by $742 thousand (-3%) to $22,256 thousand from $22,998 thousand. - **Research and Development (R&D) Expenses**: Decreased by $2,962 thousand (-24%) to $9,640 thousand from $12,602 thousand, driven by lower personnel expenses (including share-based compensation and headcount) and reduced external expenses related to ion channel programs. - Personnel related expenses: $4,795 thousand in 2026 vs $6,849 thousand in 2025. - External expenses: $3,140 thousand in 2026 vs $3,723 thousand in 2025. - Facility and other overhead expenses: $1,705 thousand in 2026 vs $2,030 thousand in 2025. - **General and Administrative (G&A) Expenses**: Decreased by $1,296 thousand (-16%) to $6,619 thousand from $7,915 thousand, primarily due to lower personnel expenses (share-based compensation and headcount) and reduced legal fees. - **Amortization of Intangibles**: Increased by $2,800 thousand (87%) to $6,028 thousand from $3,228 thousand, primarily due to a $2.9 million impairment charge on certain legacy small molecule ion channel intangible assets during Q1 2026. - **Other Operating Income, Net**: Decreased to - $46 thousand from - $750 thousand, mainly due to a lower reduction in contingent liabilities, partially offset by an increase in royalty expense. - **Interest Income**: Decreased to $487 thousand from $537 thousand, attributed to lower short-term investment balances and declining interest rates. - **Income Tax (Expense) Benefit**: Changed from a benefit of $106 thousand in 2025 to an expense of - $442 thousand in 2026. #### Cash Flow - **Net Cash Used in Operating Activities**: Decreased significantly to - $4,914 thousand for the three months ended March 31, 2026, from - $15,872 thousand in the prior-year period, primarily reflecting a lower net loss and changes in operating assets and liabilities. - **Net Cash Provided by (Used in) Investing Activities**: Shifted to $8,436 thousand provided in 2026 from - $878 thousand used in 2025, largely due to $18,000 thousand in proceeds from the maturity of short-term investments, partially offset by $9,397 thousand in purchases of short-term investments. - **Net Cash Provided by Financing Activities**: Was negligible in 2026 ($0) compared to $44 thousand in 2025. - **Cash, Cash Equivalents and Restricted Cash**: Increased to $29,606 thousand as of March 31, 2026, from $26,084 thousand at the beginning of the period. #### Unique Metrics - **Active Partners**: Maintained at 107 as of March 31, 2026. - **Active Programs**: Increased to 409 as of March 31, 2026. - **Active Clinical Programs and Approved Products**: Remained at 32 as of March 31, 2026. - **Approved Products**: Remained at 3 as of March 31, 2026. #### Future Outlook and Strategy OmniAb, Inc. anticipates continued losses due to ongoing investments in R&D, technology platform improvements, market expansion, and public company operational costs. The company’s existing cash, cash equivalents, and short-term investments of $49.1 million are expected to support operations for at least the next 12 months. OmniAb, Inc. may seek additional capital to expand its business, pursue strategic investments or acquisitions, or for other reasons, with $88.3 million remaining available under its ATM offering program. ### Related Stocks - [OABI.US](https://longbridge.com/en/quote/OABI.US.md) ## Related News & Research - [OmniAb to present at Nasdaq/LD Micro Summit Series](https://longbridge.com/en/news/297041629.md) - [OmniAb (NASDAQ:OABI) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS](https://longbridge.com/en/news/295310097.md) - [OmniAb Raises 2026 Financial Guidance | OABI Stock News](https://longbridge.com/en/news/296088999.md) - [Trøndelag Sparebank to prepay subordinated bond at 100% of par on Oct. 14](https://longbridge.com/en/news/297001082.md) - [Craig-Hallum Reaffirms Their Buy Rating on OmniAb (OABI)](https://longbridge.com/en/news/293184400.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**